-
公开(公告)号:US10590197B2
公开(公告)日:2020-03-17
申请号:US15743756
申请日:2016-07-15
Applicant: UCB Biopharma SPRL
Inventor: Helene Margaret Finney , Stephen Edward Rapecki , Kerry Louise Tyson , Michael John Wright
IPC: C07K16/28 , A61K39/00 , A01K67/027
Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
-
公开(公告)号:US10562966B2
公开(公告)日:2020-02-18
申请号:US13817961
申请日:2011-08-19
Applicant: David Paul Humphreys , Shirley Jane Peters , Ralph Adams , James Heads
Inventor: David Paul Humphreys , Shirley Jane Peters , Ralph Adams , James Heads
Abstract: The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a CH1 domain and a hinge region, wherein in each heavy chain: a. the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b. one or more of the amino acids positioned in the upper hinge region is substituted with cysteine.
-
公开(公告)号:US20190308965A1
公开(公告)日:2019-10-10
申请号:US16438348
申请日:2019-06-11
Applicant: UCB Biopharma SPRL
Inventor: Wolfgang WRASIDLO , Emily M. Stocking
IPC: C07D417/12 , C07D413/12 , C07D417/14 , C07D403/12
Abstract: The present invention relates to certain heteroaryl amide compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer and melanoma.
-
公开(公告)号:US10421816B2
公开(公告)日:2019-09-24
申请号:US15165131
申请日:2016-05-26
Applicant: UCB PHARMA S.A.
Inventor: Ralph Adams , Emma Dave , David Paul Humphreys
Abstract: The present invention provides a multivalent antibody or a heavy/light chain component thereof comprising: a heavy chain comprising a constant region fragment, said constant region fragment located between two variable domains which are not a cognate pair, the heavy chain further comprising an Fc region with at least one domain selected from CH2, CH3 and combinations thereof, with the proviso that the heavy chain contains no more than one CH1 domain and only contains two variable domains, and a light chain comprising a constant region fragment located between two variable domains which are not a cognate pair, wherein said heavy and light chains are aligned to provide a first binding site formed by a first cognate pair of variable domains and a second binding site formed by a second cognate pair of variable domains.
-
公开(公告)号:US10421814B2
公开(公告)日:2019-09-24
申请号:US15883130
申请日:2018-01-30
Applicant: UCB BIOPHARMA SPRL
Inventor: Graham Craggs , Karine Jeannine Madeleine Herve , Diane Marshall
Abstract: The present invention relates to an anti-CSF-1R antibody and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The present invention also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment.
-
公开(公告)号:US20190161536A1
公开(公告)日:2019-05-30
申请号:US16197066
申请日:2018-11-20
Inventor: Gökhan S. Hotamisligil , Mehmet F. Burak , Feyza Engin , Scott B. Widenmaier , Elisabeth Helen Roberts , Adrian Richard Moore , Carl Brendan Doyle , Ralph Adams , Karine Jeannine Madeleine Hervé , Shauna Mhairi Wales , Kerry Louise Tyson
Abstract: This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.
-
公开(公告)号:US20190119206A1
公开(公告)日:2019-04-25
申请号:US15772607
申请日:2016-10-27
Applicant: UCB Biopharma SPRL
Inventor: Thierry DEFRANCE , Jean SEPTAVAUX , Didier NUEL
IPC: C07D207/27
CPC classification number: C07D207/27 , C07D207/26
Abstract: The present invention relates to a new process for preparing brivaracetam. (Ib)
-
公开(公告)号:US10202405B2
公开(公告)日:2019-02-12
申请号:US15513357
申请日:2015-10-02
Applicant: UCB Biopharma SPRL , Sanofi
Inventor: Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm Mac Coss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
IPC: C07D519/00 , C07F7/18 , C07D471/18 , C07D487/18 , C07D493/18 , C07D491/08 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D487/08 , C07D491/18 , C07D495/08 , C07D495/18 , C07D513/18
Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
-
公开(公告)号:US20180337485A1
公开(公告)日:2018-11-22
申请号:US15777483
申请日:2016-11-17
Applicant: UCB Biopharma SPRL
Inventor: Barry Alan KNIGHT , Oliver Frederik STUMPP
IPC: H01R13/516 , H01R13/62
CPC classification number: H01R13/516 , H01R13/62
Abstract: Provided is a housing for a USB connector plug comprising a body for partly surrounding the USB connector plug, the body defining a forward aperture from which a plug head of the USB connector plug extends and a rearward aperture from which a cable of the USB connector plug extends. The body has an outer form, which defines on a first surface thereof, a thumb pad and on a second opposing surface, a finger pad. The outer form of the body is provided with a thumb push element that stands proud from a forward part of the thumb pad. The housing may also be configured as an over-housing for a conventional USB connector plug.
-
公开(公告)号:US10105359B2
公开(公告)日:2018-10-23
申请号:US15517795
申请日:2015-10-06
Applicant: UCB Biopharma SPRL
Inventor: Anne Valade , Eric Jnoff , Ali Ates , Pierre Burssens , David Skolc , Zara Sands , Benoit Mathieu
IPC: C07D217/06 , A61K31/4725 , C07D401/06 , C07D403/06 , C07D413/04
Abstract: The present invention relates to tetrahydroisoquinoline derivatives according to formula (I), which are Positive Allosteric Modulators of D1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which D1 receptors play a role.
-
-
-
-
-
-
-
-
-